Database The nucleotide sequence of the human DPP-III promoter has been submitted to the GenBank database under the accession number FJ793449
Ets-1/ Elk-1 is a critical mediator of dipeptidyl-peptidase III transcription in human glioblastoma cells
Article first published online: 2 MAR 2010
© 2010 The Authors Journal compilation © 2010 FEBS
Volume 277, Issue 8, pages 1861–1875, April 2010
How to Cite
Shukla, A. A., Jain, M. and Chauhan, S. S. (2010), Ets-1/ Elk-1 is a critical mediator of dipeptidyl-peptidase III transcription in human glioblastoma cells. FEBS Journal, 277: 1861–1875. doi: 10.1111/j.1742-4658.2010.07603.x
- Issue published online: 30 MAR 2010
- Article first published online: 2 MAR 2010
- (Received 9 November 2009, revised 25 December 2009, accepted 1 February 2010)
- electrophoretic mobility shift assays;
- site-directed mutagenesis;
- transcription factors
Dipetidyl-petidase III is a metallopeptidase involved in a number of physiological processes and its expression has been reported to increase with the histological aggressiveness of human ovarian primary carcinomas. Because no information regarding the regulation of its expression was available, experiments were designed to clone, define and characterize the promoter region of the human dipeptidyl-peptidase III (DPP-III) gene. In this study, we cloned a 1038 bp 5′-flanking DNA fragment of the human DPP-III gene for the first time and demonstrated strong promoter activity in this region. Deletion analysis revealed that as few as 45 nucleotides proximal to the transcription start site retained ∼ 40% of the activity of the full-length promoter. This promoter lacked the TATA box but contained multiple GC boxes and a single CAAT box. Similarly, two Ets-1/Elk-1-binding motifs are present in the first 25 nucleotides from the transcription start site. Binding of Ets-1/Elk-1 proteins to these motifs was visualized by electrophoretic mobility shift and chromatin immunoprecipitation assays. Mutations of these binding sites abolished not only binding of the Ets protein, but also the intrinsic promoter activity. Increased DNA-binding activity of Ets-1/Elk-1 by v-Ha-ras also augmented the mRNA level and promoter activity of this gene. Similarly, co-transfection of DPP-III promoter–reporter constructs with Ets-1 expression vector led to a significant increase in promoter activity. From these results, we conclude that Ets-1/Elk-1 plays a critical role in transcription of the human DPP-III gene.
Chang liver Ras cells
Chang liver ΔRas cells
electrophoretic mobility shift assay
extracellular regulated kinase
mitogen-activated protein kinase kinase
Dipeptidyl-peptidase III (DPP-III), a cytosolic aminopeptidase has been purified and characterized from different tissues of various animal species such as rat and human skin [1,2], bovine and human cataractous lens , rabbit and human erythrocytes , rat brain  and pancreas , monkey brain , human placenta , neutrophils , Saccharomyces cerevisiae  and Drosophila melanogaster . All mammalian DPP-IIIs require zinc ions for their maximum activity and have therefore been termed metalloaminopeptidases. The crystal structure of yeast DPP-III has been described by Baral et al. , providing an insight into its catalytic mechanism and mode of substrate binding. No endogenous substrate for this enzyme has yet been identified. However, it has broad specificity for a number of polypeptides, suggesting its involvement in the terminal stage of intracellular protein catabolism. Interestingly, DPP-III activity has been reported to increase in retroplacental serum  suggesting that it is synthesized in placental cells and released into the maternal circulation. In view of its high affinity for angiotensin II and III , the potential role of this peptidase in elevating the level of plasma angiotensin hydrolysing activity during pregnancy has been described. Similarly, it exhibits high affinity for Leu-enkephalins . These features suggest a potential role for DPP-III in the regulation of blood pressure  and in pain modulation . Human DPP-III has been shown to increase with the histological aggressiveness of human ovarian primary carcinomas . Because levels of DPP-III alter in several physiological and pathological conditions it must necessarily be amenable to regulated expression. However, no systematic study has been carried out to elucidate the regulatory molecular mechanisms associated with its expression. Therefore, this study was designed to clone and characterize the human DPP-III promoter in order to elucidate the transcriptional regulation of the gene. In this regard, we identified the region that plays an important role in determining the basal promoter activity of the gene. Furthermore, with the help of binding assays and site-directed mutagenesis, we established that Ets-1/Elk-1 play a key role in the regulation of DPP-III transcription in human glioblastoma cells.
PCR amplification, sequence analysis and demonstration of promoter activity in the 5′ upstream region of the human DPP-III gene
Using primer designs based upon the DPP-III gene located on chromosome 11q 12q13.1 of the human genome sequence (accession number NT_033903.7), we were able to amplify a single 1038 bp DNA fragment by PCR (data not shown). This fragment was cloned into a TA cloning vector and sequenced. Analysis of its nucleotide sequence showed 100% homology to the upstream region and part of the reported 5′-end of DPP-III mRNA. These results indicated that the amplified region is physically linked to exon 1 of the DPP-III gene. Nucleotide sequence analysis of the cloned 1038 bp human DPP-III promoter revealed that it contained 63.19% G + C nucleotides, no detectable TATA box, a single CAAT box and several GC boxes (Sp1-binding sites). Multiple putative transcription factor binding sites were identified in this region using the motif finder program (http://motif.genome.jp/) with high-stringency parameters for core similarity of 0.85 and matrix similarity of 0.85. As shown in Fig. 1, these motifs include NF-κB, USF, C/EBP, CREB, NF-1 and multiple binding sites for the Sp1 and Ets family of transcription factors, suggesting that the amplified region is a potential promoter. To demonstrate promoter activity in the amplified fragment, we cloned it upstream of the luciferase reporter gene in the pGL3-Basic vector. Transfection of the resulting construct (pAAS-1) into U87MG, Caov-2, Chang liver, Panc1 and NIH 3T3 cells yielded ∼ 800-, ∼ 200-, ∼ 100-, ∼ 80- and ∼25-fold higher luciferase activity respectively, compared with the pGL3-Basic transfected cells (Fig. 2). These results established that the cloned fragment is a functional DPP-III promoter.
Mapping of the transcriptional start site
As a first step towards characterization of the human DPP-III promoter, the transcriptional start site in U87MG cells was mapped using 5′-RACE. Resolution of RACE products on agarose gel revealed the amplification of a single ∼ 200 bp fragment (Fig. 3). This fragment was cloned into a TA cloning vector and six representative clones were subjected to double-stranded DNA sequencing. All clones exhibited 100% homology to DPP-III mRNA and contained the same nucleotide (G) corresponding to the 33rd nucleotide upstream of the translation initiation codon in the reported mRNA sequence (accession number NM_005700). These results suggested that this nucleotide is the transcription initiation site (marked +1 in Fig. 1).
Deletion analysis of human DPP-III promoter
In order to define the minimal promoter region and identify the functional transcription factor binding motif(s) in this region of the DPP-III gene, a series of promoter–reporter constructs with varying lengths for the 5′-region were generated. The 5′-ends of these constructs are marked () in Fig. 1. These constructs were transfected into human glioblastoma cells (U87MG) followed by estimation of the luciferase activity. The construct pAAS-2 (−781/+5), which lacks first 252 bases from the 5′-end of the full-length promoter, retained 92% of the promoter activity (∼ 740-fold promoter activity over pGL3-Basic vector) (Fig. 4A). Further deletion of 548 or more bases from the 5′-end resulted in a significant reduction in promoter activity. Constructs which lacked 548 bp (−485/+5, pAAS-3), 803 bp (−230/+5; pAAS-4), 909 bp (−123/+5; pAAS-5), 940 bp (−93/+5; pAAS-6), 980 bp (−53/+5; pAAS-7) and 993 bp (−40/+5; pAAS-8) from the 5′-end, retained 51, 48, 39, 42, 44 and 40% promoter activity, respectively, compared with the full-length promoter (Fig. 4A). All these constructs exhibited > 300-fold promoter activity compared with pGL3-Basic. Thus, 45 nucleotides (minimal promoter) from the 3′-end of the DPP-III promoter retained 40% of the full-length promoter (pAAS-1) activity (320-fold over pGL3-Basic). Sequence analysis of the minimal promoter region (−40/+5) revealed no obvious TATA or CAAT boxes. However, two perfect consensus Ets-1/Elk-1 core binding motifs (GGAAGCAGGAA) separated by three bases were present in this region (at positions −6 and −13). To elucidate the role of these motifs, we deleted 25 bases from the 3′-end of the construct pAAS-5, thus generating pAAS-9 (−124/−21). This construct, which lacked 5 bases of exon 1 and 20 bases of the promoter region, including Ets-1/Elk-1-binding motifs, exhibited no promoter activity (Fig. 4B). These results established that nucleotides between −20 and +5 are essential for DPP-III promoter activity.
To further corroborate our results, we mutated these two Ets-1/Elk-1 binding motifs sequentially in pAAS-1 using site-directed mutagenesis and assessed the promoter activities of the resulting constructs (Fig. 5). pAAS-1Mut1 (harbouring a mutated Ets-1/Elk-1 motif at position −6) and pAAS-1Mut2 (having Ets-1/Elk-1 mutated motifs at both position −6 and position −13), were transfected in U87MG cells. Mutations in the motif at −6 (pAAS-1Mut1) resulted in an 81% loss of basal promoter activity compared with the full-length construct (pAAS-1). Whereas mutations in both Ets-1/Elk-1-binding motifs (pAAS-1Mut2) resulted in a 96% loss of basal promoter activity compared with the full-length construct (pAAS-1, Fig. 5). Abolition of the promoter activity confirmed that Ets-1/Elk-1 binding motifs are essential for transcription of the human DPP-III gene. Because mutation of the motif present at the −6 position alone resulted in an 81% loss of promoter activity, we conclude that Ets-1/Elk-1-binding motifs are critical for DPP-III gene expression.
Binding of transcription factors to the minimal promoter region (-40/+5)
To show the in vivo binding of Ets-1 and Elk-1 transcription factors with the human DPP-III minimal promoter region, we performed chromatin immunoprecipitation (ChIP) assays using Ets-1 and Elk-1 antibodies. The immunoprecipitated chromatin was subjected to PCR using primers flanking the binding motifs present at positions −6 and −13 in the DPP-III promoter. Amplification of a specific 81 bp DNA fragment was observed when the DNA was immunoprecipitated using Ets-1 or Elk-1 antibodies. However, no amplification of any DNA fragment was evident when DNA was precipitated using mouse IgG (negative control) (Fig. 6). The identity of the amplified products as part of the DPP-III promoter was confirmed by DNA sequencing.
An electrophoretic mobility shift assay (EMSA) was performed to assess the specific binding of Ets-1/Elk-1 to the DPP-III minimal promoter region. EMSA was performed using nuclear extracts obtained from U87MG cells. Nucleotide fragments (23 bp) harbouring wild-type (−18/+5; Ets-Wt) or mutated (Ets-M1 and Ets-M2) Ets-1/Elk-1 motifs were used as radiolabelled probes for this purpose (Table 1). Incubation of radiolabelled Ets-Wt with the nuclear extract resulted in the formation of two DNA–protein complexes which migrated more slowly than the free radiolabelled probe (Fig. 7A,B; lanes 2). In the first complex (Fig. 7A; shift 1), nuclear proteins showed strong binding to the probe compared with the second complex (Fig. 7A; shift 2), which migrated more slowly than the first. Formation of these complexes was abrogated in the presence of a 100 molar excess of unlabelled Ets-Wt (Fig. 7B, lane 3). Incubation of either radiolabelled Ets-M1 or Ets-M2 with the nuclear lysate did not result in the formation of any such complex (Fig. 7A; lanes 3 and 4). Consistent with these results, in the presence of a 100 molar excess of unlabelled Ets-M2, no change in the binding of nuclear proteins to radiolabelled Ets-Wt was observed (Fig. 7B; lane 4). Incubation of the mixture of radiolabelled probe and nuclear lysate with antibodies specific for Ets-1/Elk-1 resulted in ‘supershifts’ of the complex (shift 1) (Fig. 7B; lanes 6 and 8). However, the formation of such complexes was not observed when antibodies were added to the nuclear lysate prior to addition of the labelled probe (Fig. 7B; lanes 5 and 7),
Upregulation of DPP-III expression and promoter activity by v-Ha-ras
Promoter deletion analysis, site-directed mutagenesis, EMSA and ChIP assays demonstrated that Ets-1 and Elk-1 play a critical role in the transcription of DPP-III gene. Most Ets family proteins are nuclear targets for phosphorylation by the RAS/mitogen-activated protein kinase (MAPK) signalling pathway. These nuclear phospho-proteins in turn influence cell proliferation, differentiation and oncogenic transformation. Our laboratory has developed a human liver cell line (Chang liver) stably expressing v-Ha-ras (M. Jain et al., unpublished results). These Chang liver ras (CLR) cells exhibited approximately twofold higher levels of pElk-1 (P ≤ 0.002) compared with cells stably transfected with the empty vector (Chang liver ΔRas; CLΔR) (Fig. 8A). Transfection of pAAS-1 in CLR and CLΔR cells demonstrated a twofold higher luciferase activity in CLR cells compared with CLΔR cells, (P < 0.001; Fig. 8B). To demonstrate that the higher DPP-III promoter activity was because of increased levels of pElk-1 in v-Ha-ras-expressing cells (CLR), we treated CLR and CLΔR cells with mitogen-activated protein kinase kinase/extracellular regulated kinase (MEK/ERK) inhibitor U0126 (Sigma-Aldrich, Urbana, IL, USA). Immunoblot analysis using antibodies specific for pERK confirmed a significant reduction in the levels of its phosphorylated form (P ≤ 0.02; Fig. 8D,E). Similarly, levels of pElk-1 were found to be decreased in U0126-treated CLR cells compared with untreated cells (P ≤ 0.003). However, CLΔR cells did not exhibit any significant difference in pElk-1 levels on treatment with the inhibitor (Fig. 8F,G). Our efforts to compare the levels of pEts-1 failed because the antibody did not work in western blots.
The effect of inhibition of the MAPK pathway by the U0126 inhibitor and the concomitant influence of pElk-1 levels on transcription of the DPP-III gene was assessed. In this regard, mRNA levels specific for the DPP-III gene were estimated in both cell lines before and after treatment with inhibitor. We observed that expression of DPP-III mRNA in CLR cells was twofold higher than in CLΔR cells (P ≤ 0.002). Treatment of CLR cells with U0126 decreased the DPP-III mRNA level by threefold (P ≤ 0.03), although there was no significant effect on DPP-III mRNA levels in treated CLΔR cells (Fig. 8H). Thus we conclude that upregulation of DPP-III expression by v-Ha-ras is mediated by increased Elk-1 phosphorylation.
Induction of DPP-III promoter activity by Ets-1
It is evident from the results presented in Fig. 2 that the DPP-III promoter exhibits minimal activity in human cell lines like Panc1 and Chang liver. Therefore, to further establish the role of Ets-1 in the transcription of DPP-III, we co-transfected Chang liver cells with DPP-III promoter–reporter construct containing wild-type (pAAS-1) or mutant (pAAS-1Mut2) Ets-1/Elk-1-binding motifs with the Ets-1 expression vector (pEts-1) in a molar ratio of 1 : 1. Simultaneously, pAAS-1 and pAAS-1Mut2 were also co-transfected along with empty Ets-1 expression vector (pcDNA3.1) and luciferase activity was assayed in all transfected cells. Co-transfection of pAAS-1 with pEts-1 resulted in a significant (P = 0.03) increase in promoter activity compared with co-transfection with empty vector (Fig. 9). However, no such difference in promoter activity was observed when pAAS-1Mut2 was co-transfected with pEts-1 or empty vector (Fig. 9). These results clearly establish that over-expression of Ets-1 induces the DPP-III promoter activity.
Human DPP-III, a metalloaminopeptidase, purified and characterized from a number of tissues, has been implicated in several physiological and pathological processes. To understand the regulation of its expression, the promoter of this peptidase has been cloned and characterized for the first time in this study.
We amplified a 1038 bp genomic fragment located upstream of the previously published DPP-III transcript (accession number NM_005700). This fragment exhibited maximal promoter activity in human glioblastoma cells compared with other human and murine cells, as assessed by luciferase reporter assays (Fig. 2). These results are in agreement with the high DPP-III activity reported in brain homogenates of rat, monkey and guinea pig [5,7,16]. The presence of DPP-III in the central nervous system facilitates the degradation of angiotensins and encephalin, suggesting its role in blood pressure regulation and in pain modulation .
Analysis of the amplified fragment (DPP-III promoter) revealed the absence of a consensus TATA box, a high GC content (63.16%), and the presence of multiple binding motifs for Sp1, suggesting that the human DPP-III gene is a housekeeping gene (Fig. 1) [17–19]. This is corroborated by reports demonstrating its expression in a wide range of tissues from different animal species [5,9,11,20]. Our results demonstrate increased DPP-III promoter activity in v-Ha-ras transformed cells. Consistent with these results, TATA-less promoters of human lysosomal cysteine cathepsins are also upregulated by malignant transformation .
Most of the TATA-less promoters are known to initiate transcription from multiple sites. However, TATA-less promoters with multiple GC boxes have been shown to initiate transcription from a single site, as in the case of nerve growth factor receptor , the cellular retinol-binding protein , endothelial nitric oxide  and genes coding for DPP-I . Similarly, we observed a single transcriptional start site located 33 nucleotides upstream of the translation initiation codon for DPP-III in U87MG cells (Fig. 1). Analysis of the DPP-III promoter sequence revealed the presence of an initiator element (Inr)-like sequence surrounding the transcription initiation site and two A/T-rich sequences at positions −29 and −24 (Fig. 1). The A/T content of the −30 sequence in an Inr-containing synthetic promoter has been shown to have a profound positive influence on the strength of the promoter, despite having minimal resemblance to the TATA consensus sequence [25,26]. The stretch of DNA between the Inr sequence and the A/T-rich region in the DPP-III promoter contains a GC box (Sp1-binding motif) and two Ets-1/Elk-1-binding motifs. Both of these transcription factors are known to help in recruitment of the transcription initiation assembly [27–29] and therefore this arrangement of nucleotides in the DPP-III promoter is probably responsible for the strong promoter activity of DPP-III in U87MG cells.
Deletion analysis of the DPP-III promoter revealed that the region between −781 and −485 bp contains several transcription factor binding motifs such as USF, C/EBP and Sp1 (Fig. 1), and removal of this region results in a 40% decrease in promoter activity (Fig. 4A). These results suggest that some or all of these motifs are important for DPP-III transcription. This analysis also suggested that the 25 nucleotides at the 3′-end of the DPP-III promoter are essential for its activity (Fig. 4B). Nucleotide sequence analysis of this region revealed the presence of two Ets-1/Elk-1-binding motifs (GGAAGCAGGAA) at positions −6 and −13. EMSA and ChIP assays established the binding of the transcription factor(s) to these motifs. Ets-1 has been shown to positively regulate urokinase plasminogen activator (uPA) expression in breast cancer, glioma, astrocytoma and meningioma cells [30,31]. Similarly, Ets transcription factor(s) regulate the expression of several other human genes such as stromelysin , prolactin and growth hormone  and chemokine . Mutations in the Ets-1/Elk-1-binding motifs abolished promoter activity (Fig. 5). This was in agreement with the EMSA results using the 23 bp DNA fragment, wherein no shift in mobility was observed, (Fig. 7). These results led us to conclude that the mutations which abolish the binding of Ets-1 and Elk-1 to DPP-III promoter result in a concomitant loss of promoter activity.
Several studies have demonstrated that Ets-binding motifs when present in a pair and in close proximity with each other, induce gene expression to a higher level [35–37]. Consistent with these reports, the DPP-III promoter containing two Ets-binding motifs (at positions −6 and −13) separated by three nucleotides exhibits robust activity (800-fold over pGL3-Basic) in U87MG cells (Fig. 2). Mutagenesis of just one of these motifs (−6 position) resulted in a > 80% decrease in promoter activity, suggesting that both motifs are essential for strong promoter activity (Fig. 5). The cooperative binding of Ets proteins as a homodimer or a heterodimer to form a ternary complex with the promoter region of several genes has been demonstrated [32,36]. Stromelysin-1 promoter is transactivated by a homo-dimer of Ets-1 through head-to-head Ets-binding sites . The DPP-III promoter contains two Ets-binding motifs arranged in a head-to-tail orientation within the first 25 bp upstream of the transcription start site. However, Ets-1 binds as a homodimer when the two motifs are present in a head-to-head orientation . In supershift assays, the mobility of the DNA–protein complex was further shifted to a similar extent by both Ets-1 and Elk-1 antibodies (Fig. 7B), suggesting the binding of both these transcription factors to their cognate motifs in this region. The formation of two DNA–protein complexes also suggests that both these transcription factors bind individually, as well as in the form of a heterodimer to the DPP-III promoter.
The N-terminal domain of Ets-1 is involved in the formation of a complex with other proteins, whereas its C-terminal domain is involved in DNA binding . By contrast, the DNA-binding domain of Elk-1 is present at its N- terminal end and C-termini allows it to form homo- or heterodimers. In our supershift experiments, we used an antibody against Ets-1 raised against its N-terminal region and an antibody against Elk-1 raised against phosphorylated Ser383 present at the C-terminus of this protein. Preincubation of nuclear proteins with antibodies completely abolished the formation of shift 2 (Fig. 7B; lanes 5 and 7). This result suggests that shift 2 was created by binding a heterodimer of Ets-1 and Elk-1 to the probe, and the N-terminus of Ets-1 and the C-terminus of Elk-1 were involved in the formation of the heterodimer. Preincubation of nuclear proteins with antibodies against Ets-1 or Elk-1 prevented the formation of any such complex, confirming the binding of a heterodimer of Ets-1 and Elk-1 to the probe. Likewise, incubation of antibodies with the DNA–protein complexes did not produce any supershift of shift 2 because the N-terminus of Ets-1 and the C-terminus of Elk-1 were involved in the formation of the heterodimer and were not therefore available for binding to their respective antibodies. However, these antibodies allowed us to identify binding of both Ets-1 and Elk-1 separately, as well as in the form of a complex to the DPP-III promoter. The slower moving complex (Fig. 7A, shift 2) showed strong binding of nuclear proteins to the probe only when antibodies were added after incubation of probe with the nuclear proteins (Fig. 7B, lanes 6 and 8) suggesting stabilization of the DNA–protein complex.
From these results it is apparent that Ets-1 and Elk-1 are involved in the formation of a ternary complex with the DPP-III promoter and in regulating its expression. In addition, Ras has been shown to mediate the phosphorylation of Ets proteins thereby increasing their transactivation ability [39,40]. In this regard, we observed significantly higher mRNA expression and promoter activity of DPP-III associated with elevated levels of phosphorylated Elk-1 in CLR cells. This further reiterates the role of Ets proteins in DPP-III expression. Finally, co-transfection of Ets-1 expression vector (pEts-1) with promoter–reporter construct harbouring wild-type (pAAS-1), but not mutated (pAAS-1Mut2), Ets-1/Elk-1-binding motifs exhibited a significant increase in promoter in Chang liver cells (Fig. 9). These results confirm that Ets-1 is necessary for DPP-III transcription and convincingly demonstrate the critical role of Ets-1/Elk-1 in the expression of this peptidase.
Materials and methods
Human glioblastoma (U87MG), ovarian carcinoma (Caov-2), pancreatic carcinoma (Panc1) and mouse fibroblast (NIH 3T3) cells (obtained from National Centre for Cell Science, Pune, India) were grown in Dulbecco’s modified Eagle’s medium (Sigma-Aldrich, St. Louis, MO, USA) containing high glucose (4.5 g·L−1 at 25 mm) and supplemented with 20 μg·mL−1 ciprofloxacin and 10% fetal bovine serum (Gibco Life Technologies, Karlsruhe, Germany) in a humidified atmosphere containing 5% CO2 at 37 °C. Chang liver cells, and stably v-Ha-ras-transfected Chang liver cells, were cultured under identical conditions in minimum essential medium containing 500 μg·mL−1 G418 (Sigma-Aldrich).
Antibodies against human Ets-1 (sc-111) and human pElk-1 (sc-8406) were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA).
Amplification and cloning of the 5′ upstream region of the human DPP-III gene
To amplify the upstream region of the DPP-III gene, HpaI- and NheI-digested total human genomic DNA was used as a template and three rounds of PCR were performed using primers designed based on human genome sequence (accession number NT_033903.7). For primary PCR, a sense primer DPP-III F1 (5′-TCCTAAGGACACCGACCAAC-3′, Fig. 1) from the upstream region and an antisense primer DPP-III R1 (5′-CAGAAAGGGAA-CGATTTTGC-3′; Fig. 1) from the first intron were used. The product of the primary PCR was diluted 100-fold and 1 μL of it was subjected to secondary PCR amplification using DPP-III F2 (5′-AGCCTCGAGACCGTGCGGGATTTCA-3′; Fig. 1) and DPP-III R2 (5′-AGTATGGATTCGCCTTGGTC-3′; Fig. 1) as nested sense and antisense primers, respectively. Similarly, a 1.0 μL aliquot of 100-fold diluted secondary PCR products was subjected to a third round of PCR using DPP-III F2 and DPP-III R3 (5′- CCCAAGCTTAACTCACTTCCTGCTTC-3′; Fig. 1) as the sense and antisense primers, respectively. The amplified fragment was subjected to double-strand DNA sequencing followed by cloning into the promoter-less reporter vector pGL3-Basic (Promega, Madison, WI, USA) upstream of the luciferase reporter gene. XhoI and HindIII restriction sites (shown in bold) were incorporated in DPP-III F2 and DPP-III R3, respectively, to facilitate the cloning of the amplified fragment. The resulting construct was named as pAAS-1 and further used for generation of deletion and mutated constructs.
For all transfections, 106 cells were plated in each well of a six-well plate 1 day prior to transfection. Next day, cells were washed twice with serum-free medium before transfecting with 1 μg of control or test plasmid DNA using Transfast™ (Promega), according to the manufacturer’s protocol. After 48 h, transfectants were washed three times with ice cold NaCl/Pi, lysed and the luciferase activity in the cell lysates measured using a dual-luciferase reporter assay system (Promega, Madison, WI, USA). The pRL-TK vector containing the Renilla luciferase gene under HSV TK promoter (Promega) were co-transfected with each construct and served as an internal control for normalization for the transfection efficiency and cell number.
Treatment of cells with the MEK inhibitor U0126
MEK inhibitor U0126, (Promega) was dissolved in dimethylsulfoxide leading to a 50 mm U0126 stock solution. Cells were serum starved for 24 h before treatment. For the experiments, U0126 was used at a concentration of 10 μg·mL−1 in medium. In parallel, control cells were treated with dimethylsulfoxide alone in the respective concentration.
Mapping of the transcription initiation site
The transcription initiation site of the human DPP-III gene was mapped using a 5′-RACE kit (Roche Applied Science, Mannheim, Germany) according to the manufacturer’s protocol. For this purpose, 3–4 μg of total RNA isolated from U87MG cells was reverse transcribed by avian myeloblastosis virus-reverse transcriptase using an antisense DPP-III-specific primer AAS-2 (5′-CTGAGCAGAGCATAGATGTAG-3′; Fig. 1). A poly(A) tail was added to the 3′-end of the purified cDNA with the help of terminal transferase. The deoxyribosyladenosine-tailed cDNA thus obtained was used as a template for PCR using an oligo(dT) anchor primer provided with the kit and an antisense DPP-III specific primer AAS-2. Another round of PCR was performed using 10-fold diluted products of primary PCR as the template and the PCR anchor primer supplied with the kit and a gene-specific primer AAS-1 (5′-GACAGGTGGTAGGCATAGAG-3′; Fig. 1). The RACE products were cloned into pGEM-TEasy (Promega) and sequenced.
Generation of promoter deletion constructs
Various 5′ promoter deletion constructs were generated by PCR using wild-type full-length DPP-III promoter–reporter construct (−1033/+ 5; pAAS-1) as the template and a common antisense primer DPP-III R3. However, different sense primers were used for each deletion construct. The PCR fragments were cloned upstream of the lucifersae reporter gene in HindIII- and XhoI-digested pGL3-Basic vector. These sites were introduced in antisense and all-sense primers, respectively to facilitate the process of cloning and have been shown in bold. The sense primers used for the different constructs were DPP-III F-786: 5′-CCCCTCGAGCCGTCCAGACCTGTAAAAG-3′ (−781/+5; pAAS-2), DPP-III F-490: 5′-CACCTCGAGCTTTGCAACTTCCAAG-3′ (−485/+5; pAAS-3), DPP-III F-129: 5′-CGACTCGAGAAGCTCGTCTTGG-3′ (−124/+5; pAAS-5), DPP-III F-98: 5′-GGCTCGAGCTGACGCCCATCC-3′ (−93/+5; pAAS–6), DPP-III F-58: 5′-GTTCTCGAGGGGGGGCGGGGTT-3′ (−53/+5; pAAS-7), DPP-III F-45: 5′-GCGCTCGAGGCAGAGCCCCAAT-3′ (−40/+5; pAAS-8). However, to generate the construct pAAS-9 (−124/−21) lacking 25 bases from the 3′-end and 909 bases from 5′-end of the promoter, the sense and antisense primers used were DPP-III F-129 and DPP-III R-21: 5′-CCGAAGCTTCCATTCATTGGGG-3′. Promoter–reporter construct pAAS-4 (−230/+5) was generated by excision of the (−1033/+5) fragment from pAAS-1 by digesting with KpnI followed by religating the larger fragment. All constructs were subjected to double-stranded DNA sequencing to rule out the inadvertent induction of mutation(s) by PCR.
Oligonucleotide-mediated mutagenesis was employed to introduce mutations into the Ets-1- and Elk-1-binding motifs present at positions −6 and −13 in the DPP-III promoter. PCR was performed using pAAS-1 as a template, DPP-IIIF2 as the sense primer and DPP-III R3M1 (5′-CCCAAGCTTAACTCACaTaCTGCTTC-3′) as the antisense primer to mutate the Ets-1/Elk-1-binding motif present at position −6. However, for mutagenesis of the Ets-1/Elk-1 motifs present at both the −6 and −13 positions, PCR was performed using same the sense primer and DPP-III R3M2 (5′-CCCAAGCTTAACTCACaTaCTGCTTaCG-3′) as the antisense primer. The nucleotides changed to mutate the Ets-1/Elk-1-binding motifs are shown in lower case. The amplified fragments were cloned and sequenced.
Preparation of nuclear extract
U87MG cells were grown in flasks until they were ∼ 80% confluent. Cells were harvested and washed twice in NaCl/Pi. A pellet of 2 × 107 cells was resuspended in 200 μL of sucrose buffer (320 mm sucrose, 10 mm Tris pH 8, 3 mm MgCl2, 2 mm Mg-acetate, 0.1 mm EDTA, 0.5% NP-40, 1 mm dithiothreitol, 0.5 mm phenylmethanesulfonyl fluoride and 10 mm NaF) and incubated on ice for 10 min, followed by centrifugation for 5 min at 500 g. The pellet was washed with sucrose buffer (without NP-40) and resuspended in 60 μL of low-salt buffer (20 mm Hepes/KOH pH 7.9, 1.5 mm MgCl2, 40 mm KCl, 0.2 mm EDTA, 25% glycerol, 0.5 mm dithiothreitol, 0.5 mm phenylmethanesulfonyl fluoride, 10 mm NaF and protease inhibitor cocktail; Sigma-Aldrich, St. Louis, IL, USA). High-salt buffer (20 mm Hepes/KOH pH 7.9, 1.5 mm MgCl2, 800 mm KCl, 0.2 mm EDTA, 25% glycerol, 1% NP-40, 0.5 mm dithiothreitol, 0.5 mm phenylmethanesulfonyl fluoride, 10 mm NaF and protease inhibitor cocktail) was added slowly in very small aliquots, while mixing with a pipette tip, followed by incubation on ice with intermittent shaking. After 45 min, the lysate was centrifuged at 14 000 g for 15 min. All the steps were carried out at 4 °C. The supernatant was removed and stored at −70 °C in small aliquots, following protein estimation using the Bradford method .
ChIP assays were performed using Imprint™ Chromatin Immunoprecipitation Kit (Sigma-Aldrich) according to the manufacturer’s protocol. Two micrograms of antibody, diluted in 100 μL antibody buffer was incubated for 90 min in the strip wells provided in the kit. Simultaneously, 1 × 106 U87MG cells were treated with 1% formaldehyde for 10 min at 25 °C to cross-link the existing DNA–protein complex(s). After treating with glycine (125 mm) to quench cross-linking, cells were processed for the isolation of nuclei. The nuclear pellet was resuspended in the shearing buffer provided in the kit and subjected to sonication using a Misonix sonicator at a power setting of 1.5 and a 100% duty cycle; the extracts were sonicated for three 10 s pulses, with 2 min on ice between pulses. Sheared chromatin was separated from the cell debris by centrifugation at 14 000 g for 10 min at 4 °C. The supernatant was incubated in wells precoated with the antibodies for 90 min. The immunoprecipitated DNA was recovered and used as a template for PCR with DPP-III F-45 and ChIPR (5′-CCGCGCCTCACCTGCAGCA-3′; Fig. 1) as the sense and antisense primers. The products were resolved on agarose gel, purified and sequenced.
Twenty-three base pair radiolabelled double-stranded fragments (from position −18 to +5 with respect to transcription initiation site mapped) containing wild-type or mutated Ets-1/Elk-1-binding motifs were end-labelled with [32P]ATP[γP] and T4 polynucleotide kinase. The unincorporated [32P]ATP[γP] was removed by Sephadex G25 column chromatography. Gel-shift assays were performed using Promega’s Gel Shift Assay System according to the manufacturer’s protocol. Binding reactions were carried out at room temperature for 30 min using 15 μg of U87MG nuclear lysate and 0.035 pmol of radiolabelled probe in buffer containing 2% glycerol, 0.5 mm MgCl2, 0.25 mm EDTA, 0.25 mm dithiothreitol, 25 mm NaCl, 5 mm Tris/HCl pH 7.5 and 0.025 mg·mL−1 poly(dI-dC)·(dI-dC). A 100 m excess of unlabelled wild-type or mutated probe was added to the binding reactions for specific and nonspecific competitive assays. For supershift assays 4 μg of the specific antibody against Ets-1 and/or pElk-1 was added to the binding reactions, followed by incubation for 4 h at room temperature. Protein–DNA complexes were resolved on 5% nondenaturing PAGE in 0.5 × TBE buffer and visualized by autoradiography.
Equal numbers of Chang liver cells stably transfected with v-Ha-ras expression vector (CLR) or empty vector (CLΔR) were washed twice with ice cold NaCl/Pi and lysed in RIPA buffer (50 mm Tris/HCl pH 7.5, 1 mm EDTA pH 8.0, 1% NP-40, 150 mm NaCl, 10 mm MgCl2, 10 mm NaF, 1 μg·mL−1 protease inhibitor cocktail). Cell lysates containing equal amounts of total protein (∼ 80 μg) were resolved on 12% denaturing SDS/PAGE and transferred on to a 0.45 μm (pore size) nitrocellulose membrane (mdi, Ambala Cantt, India). The blots were incubated with anti-pElk-1 IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and α-tubulin (Sigma, Sigma-Aldrich) followed by incubation with alkaline phosphatase-conjugated anti-rabbit IgG (Santa Cruz Biotechnology). Proteins bands were visualized using premixed 5-bromo-4-chloroindol-2-yl phosphate/Nitro Blue tetrazolium solution (Sigma-Aldrich).
Total RNA (∼ 3 μg) was reverse-transcribed using M-MuLV RT (MBI Fermentas, Vilnius, Lithuania) and random hexamers according to the manufacturer’s protocol. An aliquot containing 200 ng of the total cDNA was subjected to PCR using DPP-III F-20 (5′-GCAGGAAGTGAGTTTCGAAC-3′) and AAS1 as sense and antisense primers on a Bio-Rad I-cycler (Bio-Rad, Hercules, CA, USA). PCR was carried out in a final volume of 25 μL containing 1.5 mm MgCl2, 20 μm of each primer, 0.2 mm dNTP mix, 1 U Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA), 1 × PCR buffer (Invitrogen) and 1 × SYBER green (Invitrogen). The PCR conditions comprised of 40 cycles of denaturation 94 °C for 30 s, annealing at 59 °C for 45 s, extension at 72 °C for 1 min and fluorescence recording at 80 °C for 30 s. Similarly β-actin cDNA was also amplified using primers β-actin F (sense) (5′-AGAAAATCTGGCACCACACC-3′) and β-actin R (antisense) (5′-TAGCACAGCCTGGATAGCAA-3′), and served as the internal control. Melting-curve analysis was performed to confirm primer–dimer formation for human DPP-III or β-actin cDNAs under the above mentioned conditions. Cycle threshold (Ct) values were calculated for each PCR and relative fold change was calculated using 2−ΔΔCt method . Each set of observation was compared to the other set using a paired two-tailed t-test, assuming unequal variances among the sample means. A P-value of ≤ 0.05 was considered to be statistically significant.
The results of the present study were analysed by Student’s t-test.
We are thankful to Professor H. K. Prasad for critically reading the manuscript. The Ets-1 expression vector was a kind gift from Professor U. Pati, School of Biotechnology, JNU, New Delhi. This work was supported by a research grant [N1004] from Defence Research Development Organization (DRDO), Government of India to SSC. AAS and MJ are recipients of junior and senior research fellowships from Council of Scientific and Industrial Research, Government of India, and University Grants Commission, New Delhi, respectively.
- 142003) Activity of DPP-III in human cerebrospinal fluid derived from patients with pain. Masui 52, 257–263., , & (